Cost-effectiveness analysis of recombinant human follicle-stimulating hormone alfa(r-hFSH) and urinary highly purified menopausal gonadotropin (hMG) based on data from a large German registry.

This was a retrospective real-world evidence analysis of the costs per live birth for reference recombinant human follicle-stimulating hormone alfa (r-hFSH-alfa) versus highly purified urinary human menopausal gonadotropin (hMG-HP), based on data from a German in vitro fertilization registry (RecDate). Pregnancy and live birth rates from the RecDate real-world evidence study over three complete assisted reproductive technology (ART) cycles using the same gonadotropin drug were used as clinical inputs. Costs related to ART treatment and to drugs were obtained from public sources. Treatment with r-hFSH-alfa resulted in higher adjusted cumulative live birth rates versus hMG-HP after one (25.3% vs. 22.3%), two (30.9% vs. 27.5%), and three (31.9% vs. 28.6%) ART cycles. Costs per live birth were lower with r-hFSH-alfa versus hMG-HP after one (€17,938 vs. €20,054), two (€18,251 vs. €20,437), and three (€18,473 vs. €20,680) ART cycles. r-hFSH-alfa was found to be a cost-effective strategy compared with hMG-HP over three cycles.
Competing Interests: Declaration of competing interest KFB has received honoraria or consultation fees from Merck Healthcare KGaA, Darmstadt, Germany, Ferring, Bayer, Stiftung Endometriose Forschung, and Takeda and is a member of an advisory board for Merck. CR is an employee of Pharma Value Consulting, Switzerland. JES, ML, and TDH are employees of Merck Healthcare KGaA, Darmstadt, Germany. AA was an employee of Merck Healthcare KGaA, Darmstadt, Germany, at the time of the analysis. EF is an employee of IQVIA, Real World Solutions, London, UK. VL is an employee of IQVIA, Real World Solutions, Amsterdam, NL. RF has received honoraria for lectures from Merck Healthcare KGaA, Darmstadt, Germany, and affiliates.
(Copyright © 2022 The Authors. Published by Elsevier Ltd.. All rights reserved.)